ArticlePolish journal of radiology2026
Utility of signal enhancement ratio on DCE-MRI for detection of residual breast cancer following surgery or neoadjuvant chemotherapy - a pilot study.
Article in Polish journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Accurate detection of residual disease following breast-conserving surgery or neoadjuvant chemotherapy is essential for appropriate treatment planning in breast cancer. This retrospective pilot study aimed to evaluate the utility of the signal enhancement ratio (SER), a quantitative parameter derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), in detecting residual malignancy. Material and methods: Fourteen women who underwent 3T bilateral breast DCE-MRI at a tertiary care centre in central India were included. SER maps were generated using voxel-wise calculations, and regions of interest were placed on areas of maximum enhancement. Residual disease was confirmed histologically in 4 patients and excluded in 10 patients (8 by histopathology, 2 by long-term follow-up). Results: Median SER was significantly higher in residual disease (136.2) compared to non-residual cases (44.0, Conclusions: SER mapping may enhance diagnostic accuracy in post-treatment breast MRI, supporting its use as a quantitative adjunct.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.